Co-diagnostics
CODX
Co-diagnostics (CODX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.46
- EPS estimate
- −$3.00
- EPS surprise
- +51.33%
- Revenue surprise
- +25.31%
- Revenue
- $166,131.00
- Revenue estimate
- $132,576.00
- Reported
- Aug 13, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | −$3.00 | −$1.46 | +51.33% | $166,131.00 | SEC |
| Q1 2026 | May 14, 2026 | −$3.75 | −$4.06 | −8.27% | $145,954.00 | SEC |
| Q4 2025 | Mar 31, 2026 | −$3.60 | −$16.35 | −354.17% | $262,489.00 | SEC |
| Q3 2025 | Nov 13, 2025 | −$5.70 | −$4.80 | +15.79% | $145,380.00 | SEC |
| Q2 2025 | Aug 14, 2025 | −$7.50 | −$6.90 | +8.00% | $162,910.00 | SEC |
| Q1 2025 | May 8, 2025 | −$8.10 | −$7.20 | +11.11% | $50,277.00 | SEC |
| Q4 2024 | Mar 27, 2025 | −$10.20 | −$10.80 | −5.88% | $149,325.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$9.90 | −$9.60 | +3.03% | $641,141.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$10.20 | −$7.50 | +26.47% | $2.7M | SEC |
| Q1 2024 | May 9, 2024 | −$6.30 | −$9.30 | −47.62% | $500,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Co-diagnostics (CODX) last report earnings?
Co-diagnostics last reported on Aug 13, 2026, covering fiscal Q2 2026.
Did CODX beat earnings estimates?
Yes. Co-diagnostics reported EPS of −$1.46 for Q2 2026 against a −$3.00 estimate — a 51.33% beat.
How much revenue did CODX report last quarter?
Co-diagnostics reported $166,131.00 in revenue for Q2 2026, against a consensus estimate of $132,576.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.